Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: An update

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 2, 2009, Pages 165-181

  Smith, Winter J ^a   Drew, Richard H ^b   Perfect, John R ^c  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b Campbell University   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antifungal prophylaxis; Azole; Fungal infection; Posaconazole; Triazole

Indexed keywords

AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; PHENYTOIN; POSACONAZOLE; PROTON PUMP INHIBITOR; RAPAMYCIN; RIFABUTIN; TACROLIMUS; VORICONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; CHROMOMYCOSIS; COCCIDIOIDOMYCOSIS; CONVULSION; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG MONITORING; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FUSARIOSIS; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HISTOPLASMOSIS; HUMAN; IN VITRO STUDY; INVASIVE CANDIDIASIS; INVASIVE MYCOSIS; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; MYCOSIS; NAUSEA; NONHUMAN; ORGAN TRANSPLANTATION; OROPHARYNX CANDIDIASIS; PHAEOHYPHOMYCOSIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN NODULE; STRUCTURE ANALYSIS; TREATMENT DURATION; VOMITING; ANIMAL; ANTIFUNGAL RESISTANCE; DISEASE MODEL; DOSE CALCULATION; DRUG INTERACTION; MICROBIOLOGICAL EXAMINATION; REVIEW;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; DISEASE MODELS, ANIMAL; DRUG DOSAGE CALCULATIONS; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; TRIAZOLES;

EID: 64049088064     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.7.2.165     Document Type: Article

References (115)

1. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin. Infect. Dis. 26(2), 259-272 (1998).
2. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case - control studies. Eur. J. Clin. Microbiol. Infect. Dis. 25(7), 419-425 (2006).
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case - fatality rate: systematic review of the literature. Clin. Infect. Dis. 32(3), 358-366 (2001).
4. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41(5), 634-653 (2005).
5. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34(7), 909-917 (2002).
6. Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 38(9), 1237-1242 (2004).
7. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin. Infect. Dis. 43(Suppl. 1), S28-S39 (2006).
8. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 64(18), 1997-2020 (2004).
9. Groll AH, Walsh TJ. Posaconazole: Clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti Infect. Ther. 3(4), 467-487 (2005).
10. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 58(6), 612-624 (2004).
11. Dodds Ashley ES, Alexander BD. Posaconazole. Drugs Today (Barc.) 41(6), 393-400 (2005).
12. Keating GM. Posaconazole. Drugs 65(11), 1553-1567 (2005).
13. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 5(12), 775-785 (2005).
14. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48(2), 568-574 (2004).
15. Nomeir AA, Pramanik BN, Heimark L et al. Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048). J. Mass Spectrom. 43(4), 509-517 (2008).
16. Bennett F, Saksena AK, Lovey RG et al. Hydroxylated analogues of the orally active broad spectrum antifungal, SCH 51048 (1), and the discovery of posaconazole [SCH 56592; 2 or (S,S)-5]. Bioorg. Med. Chem. Lett. 16(1), 186-190 (2006).
17. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12(4), 501-517 (1999).
18. Munayyer HK, Mann PA, Chau AS et al. Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds. Antimicrob. Agents Chemother. 48(10), 3690-3696 (2004).
19. Cowen LE. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat. Rev. Microbiol. 6(3), 187-198 (2008).
20. Clinical Laboratory and Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - Second Edition M27-A2. Clinical Laboratory and Standards Institute, PA, USA (2002).
21. Clinical Laboratory and Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard M38-A. Clinical Laboratory and Standards Institute, PA, USA (2002).
22. Subcommittee on Antifungal Susceptibility Testing of the European Committee for Antimicrobial Susceptibility Testing (AFST-EUCAST). EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14(4), 398-405 (2002).
23. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 43(8), 3884-3889 (2005).
24. Pfaller MA, Messer SA, Boyken L et al. In vitro activities of voricanazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48(3), 201-205 (2004).
25. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50(6), 2009-2015 (2006).
26. Lortholary O, Dannaoui E, Raoux D et al. In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. Antimicrob. Agents Chemother. 51(9), 3378-3380 (2007).
27. Spreghini E, Maida CM, Tomassetti S et al. Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. Antimicrob. Agents Chemother. 52(6), 1929-1933 (2008).
28. Carrillo-Muñoz AJ, Quindos G, Ruesga M et al. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J. Antimicrob. Chemother. 55(3), 317-319 (2005).
29. Torres-Rodríguez JM, Alvarado-Ramírez E, Murciano F, Sellart M. MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococcus gattii. J. Antimicrob. Chemother. 62(1), 205-206 (2008).
30. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51(1), 45-52 (2003).
31. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal Hgents. Clin. Microbiol. Rev. 12(1), 40-79 (1999).
32. Torres-Narbona M, Guinea J, Martínez-Alarcón J, Peláez T, Bouza E. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob. Agents Chemother. 51(3), 1126-1129 (2007).
33. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob. Agents Chemother. 51(7), 2587-2590 (2007).
34. Wheat LJ, Connolly P, Smedema M et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J. Antimicrob. Chemother. 57(6), 1235-1239 (2006).
35. Mann PA, Parmegiani RM, Wei SQ et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14α-demethylase. Antimicrob. Agents Chemother. 47(2), 577-581 (2003).
36. Chau AS, Chen G, McNicholas PM, Mann PA. Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae. Antimicrob. Agents Chemother. 50(11), 3917-3919 (2006).
37. Li X, Brown N, Chau AS et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J. Antimicrob. Chemother. 53(1), 74-80 (2004).
38. Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, Redding SW. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob. Agents Chemother. 49(8), 3544-3545 (2005).
39. Spreghini E, Maida CM, Milici ME, Scalise G, Barchiesi F. Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. Antimicrob. Agents Chemother. 52(2), 513-517 (2008).
40. Perkhofer S, Lugger H, Dierich MP, Lass-Florl C. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro. Antimicrob. Agents Chemother. 51(2), 791-793 (2007).
41. Guembe M, Guinea J, Pelaez T, Torres-Narbona M, Bouza E. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob. Agents Chemother. 51(9), 3457-3458 (2007).
42. Ballester F, Pastor FJ, Guarro J. In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus. J. Antimicrob. Chemother. 61(3), 755-757 (2008).
43. Perkhofer S, Locher M, Cuenca-Estrella M et al. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob. Agents Chemother. 52(7), 2636-2638 (2008).
44. Najvar LK, Cacciapuoti A, Hernandez S et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob. Agents Chemother. 48(3), 758-764 (2004).
45. Cacciapuoti A, Gurnani M, Halpern J, Norris C, Patel R, Loebenberg D. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob. Agents Chemother. 49(2), 638-642 (2005).
46. Cacciapuoti A, Halpern J, Mendrick C, Norris C, Patel R, Loebenberg D. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob, Agents Chemother. 50(7), 2587-2590 (2006).
47. Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE Jr, Spellberg B. Posaconazole mono- or combination therapy for the treatment of murine zygomycosis. Antimicrob. Agents Chemother. 53(2), 772-775 (2009).
48. Rodriguez MM, Serena C, Marine M, Pastor FJ, Guarro J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob. Agents Chemother. 52(10), 3786-3788 (2008).
49. Gonzalez GM, Robledo E, Saldivar D, Gonzalez G, Bosques F, Garza E. Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model. Med. Mycol. 45(3), 221-224 (2007).
50. Ullmann AJ, Krammes E, Sommer S et al. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats. J. Antimicrob. Chemother. 60(5), 1080-1084 (2007).
51. Imai JK, Singh G, Clemons KV, Stevens DA. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother. 48(10), 4063-4066 (2004).
52. Barchiesi F, Spreghini E, Santinelli A et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob. Agents Chemother. 51(1), 73-77 (2007).
53. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother. 46(7), 2310-2312 (2002).
54. Dannaoui E, Meis JFGM, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47(11), 3647-3650 (2003).
55. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47(9), 2788-2795 (2003).
56. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57(2), 218-222 (2004).
57. Ezzet F, Wexler D, Courtney R, Krishna G, Laughlin M et al. Oral bioavailability of posaconazole in fasted healthy subjects - comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44(2), 211-220 (2005).
58. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. DOI:10.1128/AAC.01034-01008. (2008).
59. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. 48(3), 804-808 (2004).
60. Sansone-Parsons A, Krishna G, Calzetta A et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother. 50(5), 1881-1883 (2006).
61. Krishna G, Sansone-Parsons A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five Phase 1 studies. Presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting. Anaheim, CA, USA, 3-7 December 2006.
62. Krieter P, Flannery B, Musick T et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob. Agents Chemother. 48(9), 3543-3551 (2004).
63. Varkey J, Krishna G, Vickery D et al. The pharmacokinetics of posaconazole administered orally versus via a nasogastric tube in healthy subjects. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, 19-22 April 2008.
64. Gubbins PO, Krishna G, Sansone-Parsons A et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob. Agents Chemother. 50(6), 1993-1999 (2006).
65. Sansone-Parsons A, Krishna G, Simon J et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 51(2), 495-502 (2007).
66. Courtney R, Sansone A, Smith W et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol. 45(2), 185-192 (2005).
67. Moton A, Ma L, Krishna G, Malavade D, Preston R, McLeod J. The safety, tolerability, and pharmacokinetics of the antifungal posaconazole in hepatic impairment. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, 19-22 April 2008.
68. Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Comely OA. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28(10), 1223-1232 (2008).
69. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27(12), 1627-1636 (2007).
70. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356(4), 335-347 (2007).
71. Ullmann AJ, Cornely OA, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50(2), 658-666 (2006).
72. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother. 51(3), 812-818 (2007).
73. Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17(2), 268-280 (2004).
74. Soczo G, Kardos G, McNicholas PM et al. Correlation of posaconazole minimum fungicidal-concentration and time - kill test against nine Candida species. J. Antimicrob. Chemother. 60(5), 1004-1009 (2007).
75. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J. Antimicrob. Chemother. 46(2), 229-234 (2000).
76. Andes D, Marchillo K, Conklin R et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48(1), 137-142 (2004).
77. Turnidge JD, Gudmundsson S, Vogelman B, Craig WA. The postantibiotic effect of antifungat agents against common pathogenic yeasts. J. Antimicrob. Chemother. 34(1), 83-92 (1994).
78. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44(4), 1108-1111 (2000).
79. Cornely OA, Maertens J, Winston DJ et al. Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356(4), 348-359 (2007).
80. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N. Engl. J. Med. 356(4), 409-411 (2007).
81. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46(3), 327-360 (2008).
82. Vazquez JA, Skiest DJ, Nieto L et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis. 42(8), 1179-1186 (2006).
83. Skiest DJ, Vazquez JA, Anstead GM et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin. Infect. Dis. 44(4), 607-614 (2007).
84. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin. Trials 8(2), 86-97 (2007).
85. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44(1), 2-12 (2007).
86. Hachem RY, Langston AA, Graybill JR et al. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J. Antimicrob. Chemother. 62(6), 1386-1391 (2008).
87. Raad II, Hanna HA, Boktour M et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22(3), 496-503 (2008).
88. Greenberg RN, Mullane K, Van Burik JAH et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50(1), 126-133 (2006).
89. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42(7), E61-E65 (2006).
90. Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42(10), 1398-1403 (2006).
91. Restrepo A, Tobon A, Clark B et al. Salvage treatment of histoplasmosis with posaconazole. J. Infect. 54(4), 319-327 (2007).
92. Stevens DA, Rendon A, Gaona-Flores V, Catanzaro A, Graybill JR et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 132(3), 952-958 (2007).
93. Catanzaro A, Cloud GA, Stevens DA et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin. Infect. Dis. 45(5), 562-568 (2007).
94. Graybill JR, Najvar LK, Johnson E, Bocanegra R, Loebenberg D. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob. Agents Chemother. 48(6), 2288-2291 (2004).
95. Negroni R, Helou SH, Petri N et al. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin. Infect. Dis. 38(3), e15-e20 (2004).
96. Negroni R, Tobon A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev. Inst. Med. Trop. Sao Paulo 47(6), 339-346 (2005).
97. Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA, Hassounah M, Rinaldi MG, Sutton DA. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med. Mycol. 43(1), 91-95 (2005).
98. Pitisuttithum P, Negroni R, Graybill JR et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 56(4), 745-755 (2005).
99. Alexander BD, Perfect JR, Daly JS et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 86(6), 791-796 (2008).
100. Raad II, Graybill JR, Bustamante AB et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis. 42(12), 1726-1734 (2006).
101. Pedicone L, Ullmann A, Graybill J et al. Comparison of posaconazole adverse event profiles in healthy volunteers and in patients with invasive fungal infections. Presented at: 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Copenhagen, Denmark, 2-5 April 2005.
102. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr. Med. Res. Opin. 23(6), 1415-1422 (2007).
103. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr. Med. Res. Opin. 23(3), 545-552 (2007).
104. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci. 21(5), 645-653 (2004).
105. Noxafil® (posaconazole), oral suspension product information. Schering-Plough, NJ, USA (2008).
106. Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J. Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastrointestinal motility on absorption and pharmacokinetics of the antifungal posaconazole. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, 19-22 April 2008.
107. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 27(6), 825-834 (2007).
108. Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effect of oral posaconazole on the pharmacokinetics of sirolimus. Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007.
109. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J. Antimicrob. Chemother. 61(1), 17-25 (2008).
110. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther. Drug Monit. 30(2), 167-172 (2008).
111. Collins CD, Ellis JJ, Kaul DR. Comparative cost - effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am. J. Health. Syst. Pharm. 65(23), 2237-2243 (2008).
112. Stam WB, O'Sullivan AK, Rijnders B et al. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in The Netherlands. Eur. J. Haematol. 81(6), 467-474 (2008).
113. Tahami Monfared AA, O'Sullivan AK, Papadopoulos G. Posaconazole versus standard azole therapy in the prophylaxis against invasive fungal infeections among high-risk neutropenic patients in Canada: a cost - effectiveness anaylsis. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, 19-22 April 2008.
114. Herbrecht R, Rajagopalan S, Danna R, Papadopoulos G. Comparative posaconazole versus other antifungals all-cause mortality and cost analyses in patients with refractory invasive aspergillosis. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007.
115. Tahami Monfared AA, Rajagopalan S, Danna R, Papadopoulos G. Economic evaluation of posaconazole compared with other antifungal therapies in patients with refractory invasive aspergillosis in Canada. Presented at: 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona, Spain, 19-22 April 2008.